Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines
Qian Zhu, Guang-Nao Zhou, Jing Guo · 2026
Read Economic burden of MDR/RR-TB and implementation of a treatment subsidy policy in Lishui City, China: a retrospective study following strobe guidelines by Qian Zhu, Guang-Nao Zhou, Jing Guo (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13556018.txt.
Description
Qian Zhu, Guang-Nao Zhou, and Jing Guo studied in 2026 what drug-resistant tuberculosis costs patients in Lishui City, Zhejiang Province, and how a local subsidy softened that cost. They surveyed 117 people treated for multidrug-resistant or rifampicin-resistant disease between 2017 and 2022, collecting treatment histories, medical bills, insurance payments, and subsidy records.
Median direct medical costs came to roughly sixty-five thousand yuan per patient. Insurance covered a large share, subsidies cut what remained, and families still paid a median of just over eight thousand yuan themselves. Patients whose subsidy fell below the median amount had notably worse treatment outcomes, while about three quarters of the group completed treatment successfully. The authors say the policy helps, though stronger study designs are needed to prove its effect.
Catalog record
| CREATOR | Qian Zhu, Guang-Nao Zhou, Jing Guo |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44571 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |